CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. PRIM
6. DPZ
7. NAVN
8. NVDA
9. DFTX
10. META

Go back to CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

CTI BioPharma (CTIC) PT Raised to $12 at Brookline Capital Markets Following FDA Approval

March 1, 2022 10:13 AM EST

Brookline Capital Markets analyst Leah Rush Cann raised the price target on CTI BioPharma (NASDAQ: CTIC) to $12.00 (from $7.20) while maintaining a Buy rating following FDA approval for Pacritinib (Vonjo) in Myelofibrosis.

The analyst commented, "The timing of this FDA-approval is as expected and the prescribing label, with no black box warning and an... More

CTI BioPharma (CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO

March 1, 2022 7:17 AM EST

CTI BioPharma (NASDAQ: CTIC) Climbs 37% Following Accelerated FDA Approval of VONJO

... More